- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07634640
Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction
June 4, 2026 updated by: University of Florida
Omega-3 Fatty Acids and Myocardial Inflammation in HFpEF: Preliminary Data and Next Steps
Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
70
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ellen C Keeley, MD, MS
- Phone Number: 800-265-0820
- Email: ellen.keeley@medicine.ufl.edu
Study Contact Backup
- Name: Vanessa H Scheuble
- Phone Number: 800-555-0820
- Email: Vanessa.scheuble@medicine.ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Recruiting
- University of Florida
-
Contact:
- Ellen C Keeley, MD, MS
- Phone Number: 800-265-0820
- Email: ellen.keeley@medicine.ufl.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- HFpEF
Exclusion Criteria:
- Renal insufficiency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Single arm study of subjects with HFpEF
Subjects with HFpEF undergo a baseline gadolinium based cardiac MRI and the same day they undergo an iron infusion.
Three days later they return for a follow-up cardiac MRI and the iron that has been administered 72 hours ago serves as the contrast media
|
Ferumoxytol infusion followed by cardiac MRI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
detection of inflammation
Time Frame: 72 hours
|
72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ellen C Keeley, MD, MS, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 3, 2023
Primary Completion (Estimated)
May 31, 2027
Study Completion (Estimated)
May 31, 2027
Study Registration Dates
First Submitted
June 4, 2026
First Submitted That Met QC Criteria
June 4, 2026
First Posted (Actual)
June 9, 2026
Study Record Updates
Last Update Posted (Actual)
June 9, 2026
Last Update Submitted That Met QC Criteria
June 4, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 202300847
- 26BIPA1622606 (Other Grant/Funding Number: American Heart Association)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure With Preserved Ejection Fraction (HFPEF)
-
Cairo UniversityActive, not recruitingHFpEF - Heart Failure with Preserved Ejection FractionEgypt
-
University of UlsterUlster Hospital, Northern IrelandCompletedHeart Failure With Preserved Ejection Fraction (HFPEF)United Kingdom
-
Chinese Academy of Medical Sciences, Fuwai HospitalEnrolling by invitationHeart Failure With Preserved Ejection Fraction (HFPEF)
-
Vasa TherapeuticsRecruitingHeart | Heart Failure With Preserved Ejection Fraction (HFPEF)United States
-
The First Affiliated Hospital of Air Force Medicial...Not yet recruitingChronic Heart Failure | Heart Failure With Preserved Ejection Fraction (HFPEF)China
-
Weill Medical College of Cornell UniversityNational Institute on Aging (NIA); Kaiser Foundation Research InstituteEnrolling by invitationHeart Failure | HFpEF - Heart Failure With Preserved Ejection Fraction | HFpEFUnited States
-
Xinjiang Medical UniversityNot yet recruitingChronic Heart Failure | Heart Failure With Reduced Ejection Fraction (HFrEF) | Heart Failure With Preserved Ejection Fraction (HFPEF) | Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)China
-
Herlev and Gentofte HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsNot yet recruitingHeart Failure With Preserved Ejection Fraction (HFPEF)Denmark
-
University Clinical Hospital MostarCompletedThe Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEFHemodialysis | Heart Failure With Preserved Ejection Fraction (HFPEF) | Sacubitril/ValsartanBosnia and Herzegovina
-
Universidad Pública de NavarraComplejo Hospitalario de Navarra; NavarraBiomed Biomedical Research Center; Centro... and other collaboratorsEnrolling by invitationHeart Failure With Preserved Ejection Fraction (HFPEF)Spain
Clinical Trials on Ferumoxytol infusion
-
University of Wisconsin, MadisonEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Michael IvNational Cancer Institute (NCI)WithdrawnChildhood Brain NeoplasmUnited States
-
Auerbach Hematology Oncology Associates P CAMAG Pharmaceuticals, Inc.CompletedIron Deficiency AnemiaUnited States
-
Allegheny Singer Research Institute (also known...Active, not recruitingLiver Neoplasms | Hepatocellular Carcinoma | Liver Metastases | Liver Cancer | Liver Carcinoma | Hepatocellular Cancer | Hepatic Cirrhosis | Hepatic Carcinoma | Hepatic AtrophyUnited States
-
Massachusetts General HospitalCompletedPapillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node MetastasisUnited States
-
University of UtahCompletedMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Secondary Progressive Multiple SclerosisUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Radiological Society of North AmericaTerminatedStage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Locally Advanced Rectal CarcinomaUnited States
-
Michael IvCompletedBrain Injury | Brain Cancer | Brain Tumors | Primary Brain Neoplasm | Ischemic Cerebrovascular Accident | Central Nervous System Degenerative Disorder | Central Nervous System Infectious Disorder | Central Nervous System Vascular Malformation | Hemorrhagic Cerebrovascular AccidentUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science University; National... and other collaboratorsTerminatedPancreatic Adenocarcinoma | Familial Pancreatic Cancer | Pancreatic Intraductal Papillary-Mucinous NeoplasmUnited States
-
Min ZhouRecruitingVenous DiseasesChina